Choose a language and wait for the translated text.
Shots:
Evotec’s strategic protein degradation partnership with Bristol Myers Squibb has received a second IND acceptance from the US FDA; the accepted candidate, a cereblon E3 ligase modulator (CELMoD), is expected to enter a P-I trial in 2027
The first candidate produced under the partnership entered a P-I trial in advanced clear cell renal cell carcinoma in Mar 2026
Initiated in 2018 & expanded in 2022, the partnership combines Evotec’s multi-omics screening, AI-supported data analytics & drug design capabilities with BMS’ CELMoD agent library to advance molecular glue degraders in oncology & beyond
Ref: Evotec | Image: Evotec | Bristol Myers Squibb | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
The post Evotec and Bristol Myers Squibb Receive the US FDA’s Second IND Acceptance Under Their Protein Degradation Partnership appeared first on PharmaShots.